Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication

Miho Asano, Marcia L Finlayson, Miho Asano, Marcia L Finlayson

Abstract

Fatigue is a common symptom of multiple sclerosis (MS) with negative impacts extending from general functioning to quality of life. Both the cause and consequences of MS fatigue are considered multidimensional and necessitate multidisciplinary treatment for successful symptom management. Clinical practice guidelines suggest medication and rehabilitation for managing fatigue. This review summarized available research literature about three types of fatigue management interventions (exercise, education, and medication) to provide comprehensive perspective on treatment options and facilitate a comparison of their effectiveness. We researched PubMed, Embase, and CINAHL (August 2013). Search terms included multiple sclerosis, fatigue, energy conservation, Amantadine, Modafinil, and randomized controlled trial. The search identified 230 citations. After the full-text review, 18 rehabilitation and 7 pharmacological trials targeting fatigue were selected. Rehabilitation interventions appeared to have stronger and more significant effects on reducing the impact or severity of patient-reported fatigue compared to medication. Pharmacological agents, including fatigue medication, are important but often do not enable people with MS to cope with their existing disabilities. MS fatigue affects various components of one's health and wellbeing. People with MS experiencing fatigue and their healthcare providers should consider a full spectrum of effective fatigue management interventions, from exercise to educational strategies in conjunction with medication.

Figures

Figure 1
Figure 1
Review flow diagram.
Figure 2
Figure 2
Forest plots.

References

    1. Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clinical Infectious Diseases. 1994;18(supplement 1):S79–S83.
    1. Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. Journal of the Neurological Sciences. 2002;205(1):51–58.
    1. Hadjimichael O, Vollmer T, Oleen-Burkey M. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health and Quality of Life Outcomes. 2008;6(article 100)
    1. Bakshi R, Shaikh ZA, Miletich RS, et al. Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Multiple Sclerosis. 2000;6(3):181–185.
    1. Chatterton H, Spearing RM. Understanding fatigue in multiple sclerosis. Physical Therapy Reviews. 2006;11(4):235–245.
    1. Kesselring J, Beer S. Symptomatic therapy and neurorehabilitation in multiple sclerosis. The Lancet Neurology. 2005;4(10):643–652.
    1. Bakshi R. Fatigue associated with multiple sclerosis: diagnosis, impact and management. Multiple Sclerosis. 2003;9(3):219–227.
    1. Kirshbaum M. Pharmacologic treatments for fatigue associated with palliative care. Clinical Journal of Oncology Nursing. 2011;15(4):438–439.
    1. Pucci E, Branãs P, D’Amico R, Giuliani G, Solari A, Taus C. Amantadine for fatigue in multiple sclerosis. The Cochrane Database of Systematic Reviews. 2007;(1)CD002818
    1. Pilutti LA, Greenlee TA, Motl RW, Nickrent MS, Petruzzello SJ. Effects of exercise training on fatigue in multiple sclerosis: a meta-analysis. Psychosomatic Medicine. 2013;75(6):575–580.
    1. Blikman LJ, Huisstede BM, Kooijmans H, Stam HJ, Bussmann JB, van Meeteren J. Effectiveness of energy conservation treatment in reducing fatigue in multiple sclerosis: a systematic review and meta-analysis. Archives of Physical Medicine and Rehabilitation. 2013;94(7):1360–1376.
    1. Kohli I, Kataria A, Kaushik P, Jindal R, Aggarwal A. Effect of cognitive behavioural therapy on multiple sclerosis fatigue: a systematic review of randomised control trials. Value in Health. 2012;15(7):A545–A546.
    1. National Multiple Sclerosis Society. Treatment recommendations for managing fatigue. 2013, .
    1. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Archives of Neurology. 1989;46(10):1121–1123.
    1. Amtmann D, Bamer AM, Noonan V, Lang N, Kim J, Cook KF. Comparison of the psychometric properties of two fatigue scales in multiple sclerosis. Rehabilitation Psychology. 2012;57(2):159–166.
    1. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. British Medical Journal. 2011;343d5928
    1. Fuhrer MJ. Overview of clinical trials in medical rehabilitation: impetuses, challenges, and needed future directions. American Journal of Physical Medicine & Rehabilitation. 2003;82(10, supplement):S8–S15.
    1. Durlak JA. How to select, calculate, and interpret effect sizes. Journal of Pediatric Psychology. 2009;34(9):917–928.
    1. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ, USA: Lawrence Erlbaum Associates; 1988.
    1. Cohen J. A power primer. Psychological Bulletin. 1992;112(1):155–159.
    1. Higgins JP, Green S, Deeks J, Altman D. Cochrane Handbook for Systematic Reviews of Interventions: Analyzing Data and Undertaking Meta-Analysis. Chichester, UK: John Wiley & Sons; 2008.
    1. Cochrane Collaboration. Cochrane collaboration open learning material: diversity and heterogeneity. 2002, .
    1. Asano M, Dawes DJ, Arafah A, Moriello C, Mayo NE. What does a structured review of the effectiveness of exercise interventions for persons with multiple sclerosis tell us about the challenges of designing trials? Multiple Sclerosis. 2009;15(4):412–421.
    1. Rietberg MB, Brooks D, Uitdehaag BM, Kwakkel G. Exercise therapy for multiple sclerosis. The Cochrane Database of Systematic Reviews. 2005;(1)CD003980
    1. Kargarfard M, Etemadifar M, Baker P, Mehrabi M, Hayatbakhsh R. Effect of aquatic exercise training on fatigue and health-related quality of life in patients with multiple sclerosis. Archives of Physical Medicine and Rehabilitation. 2012;93(10):1701–1708.
    1. Hebert JR, Corboy JR, Manago MM, Schenkman M. Effects of vestibular rehabilitation on multiple sclerosis-related fatigue and upright postural control: a randomized controlled trial. Physical Therapy. 2011;91(8):1166–1183.
    1. Velikonja O, Čurić K, Ožura A, Jazbec SŠ. Influence of sports climbing and yoga on spasticity, cognitive function, mood and fatigue in patients with multiple sclerosis. Clinical Neurology and Neurosurgery. 2010;112(7):597–601.
    1. Dalgas U, Stenager E, Jakobsen J, et al. Fatigue, mood and quality of life improve in MS patients after progressive resistance training. Multiple Sclerosis. 2010;16(4):480–490.
    1. Mostert S, Kesselring J. Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis. Multiple Sclerosis. 2002;8(2):161–168.
    1. van den Berg M, Dawes H, Wade DT, et al. Treadmill training for individuals with multiple sclerosis: a pilot randomised trial. Journal of Neurology, Neurosurgery and Psychiatry. 2006;77(4):531–533.
    1. Klefbeck B, Hamrah NJ. Effect of inspiratory muscle training in patients with multiple sclerosis. Archives of Physical Medicine and Rehabilitation. 2003;84(7):994–999.
    1. Cakt BD, Nacir B, Genc H, et al. Cycling progressive resistance training for people with multiple sclerosis: a randomized controlled study. American Journal of Physical Medicine & Rehabilitation. 2010;89(6):446–457.
    1. Hayes HA, Gappmaier E, Lastayo PC. Effects of high-intensity resistance training on strength, mobility, balance, and fatigue in individuals with multiple sclerosis: a randomized controlled trial. Journal of Neurologic Physical Therapy. 2011;35(1):2–10.
    1. Oken BS, Kishiyama S, Zajdel D, et al. Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology. 2004;62(11):2058–2064.
    1. Finlayson M, Preissner K, Cho C, Plow M. Randomized trial of a teleconference-delivered fatigue management program for people with multiple sclerosis. Multiple Sclerosis. 2011;17(9):1130–1140.
    1. Mathiowetz VG, Finlayson ML, Matuska KM, Chen HY, Luo P. Randomized controlled trial of an energy conservation course for persons with multiple sclerosis. Multiple Sclerosis. 2005;11(5):592–601.
    1. Hugos CL, Copperman LF, Fuller BE, Yadav V, Lovera J, Bourdette DN. Clinical trial of a formal group fatigue program in multiple sclerosis. Multiple Sclerosis. 2010;16(6):724–732.
    1. Grossman P, Kappos L, Gensicke H, et al. MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology. 2010;75(13):1141–1149.
    1. Kos D, Duportail M, D’hooghe MB, Nagels G, Kerckhofs E. Multidisciplinary fatigue management programme in multiple sclerosis: a randomized clinical trial. Multiple Sclerosis. 2007;13(8):996–1003.
    1. Moss-Morris R, McCrone P, Yardley L, van Kessel K, Wills G, Dennison L. A pilot randomised controlled trial of an Internet-based cognitive behavioural therapy self-management programme (MS Invigor8) for multiple sclerosis fatigue. Behaviour Research and Therapy. 2012;50(6):415–421.
    1. van Kessel K, Moss-Morris R, Willoughby E, Chalder T, Johnson MH, Robinson E. A randomized controlled trial of cognitive behavior therapy for multiple sclerosis fatigue. Psychosomatic Medicine. 2008;70(2):205–213.
    1. Mohr DC, Hart SL, Goldberg A. Effects of treatment for depression on fatigue in multiple sclerosis. Psychosomatic Medicine. 2003;65(4):542–547.
    1. Shaygannejad V, Janghorbani M, Ashtari F, Zakeri H. Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Neurological Research. 2012;34(9):854–858.
    1. Tomassini V, Pozzilli C, Onesti E, et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. Journal of the Neurological Sciences. 2004;218(1-2):103–108.
    1. Ashtari F, Fatehi F, Shaygannejad V, Chitsaz A. Does amantadine have favourable effects on fatigue in Persian patients suffering from multiple sclerosis? Neurologia i Neurochirurgia Polska. 2009;43(5):428–432.
    1. Krupp LB, Coyle PK, Doscher C, et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology. 1995;45(11):1956–1961.
    1. The Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. The Canadian MS Research Group. The Canadian Journal of Neurological Sciences. 1987;14(3):273–278.
    1. Möller F, Poettgen J, Broemel F, Neuhaus A, Daumer M, Heesen C. HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis. Multiple Sclerosis. 2011;17(8):1002–1009.
    1. Stankoff B, Waubant E, Confavreux C, et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology. 2005;64(7):1139–1143.
    1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology. 1983;33(11):1444–1452.
    1. Kurtzke JF. Disability rating scales in multiple sclerosis. Annals of the New York Academy of Sciences. 1984;436:347–360.
    1. Wingerchuk DM, Benarroch EE, O’Brien PC, et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology. 2005;64(7):1267–1269.
    1. Rossini PM, Pasqualetti P, Pozzilli C, et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Multiple Sclerosis. 2001;7(6):354–358.
    1. Mayo Clinic. Aspirin for treatment of multiple sclerosis-related fatigue. , NLM Identifier: NCT00467584, National Library of Medicine, Bethesda, Md, USA, 2007 .
    1. Barlow J, Wright C, Sheasby J, Turner A, Hainsworth J. Self-management approaches for people with chronic conditions: a review. Patient Education and Counseling. 2002;48(2):177–187.
    1. Bodenheimer T. Interventions to improve chronic illness care: evaluating their effectiveness. Disease Management. 2003;6(2):63–71.
    1. Norris SL, Engelgau MM, Narayan KMV. Effectiveness of self-management training in type 2 diabetes: a systematic review of randomized controlled trials. Diabetes Care. 2001;24(3):561–587.
    1. White AT, Wilson TE, Davis SL, Petajan JH. Effect of precooling on physical performance in multiple sclerosis. Multiple Sclerosis. 2000;6(3):176–180.
    1. Attarian HP, Brown KM, Duntley SP, Carter JD, Cross AH. The relationship of sleep disturbances and fatigue in multiple sclerosis. Archives of Neurology. 2004;61(4):525–528.
    1. Bol Y, Smolders J, Duits A, Lange IMJ, Romberg-Camps M, Hupperts R. Fatigue and heat sensitivity in patients with multiple sclerosis. Acta Neurologica Scandinavica. 2012;126(6):384–389.
    1. Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology. Implementation Science. 2010;5(article 69)

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj